Global Dialysis - Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free ... (Centre Daily Times)

Phase III Study Showed Tarceva in Combination With Avastin as First-Line Maintenance Therapy Improved Progression-Free ... (Centre Daily Times)

Genentech, Inc. (NYSE:DNA) today announced that a Phase III study (ATLAS) of Tarceva® (erlotinib) in combination with Avastin® (bevacizumab) as maintenance therapy following initial treatment with Avastin plus chemotherapy in advanced non-small cell lung cancer (NSCLC) met its primary endpoint. The study was stopped early on the recommendation of an independent data safety monitoring board after ...